Zanubrutinib as a salvage therapy for ibrutinib-resistant chronic lymphocytic leukemia: a case report
Year: 2025
Type: article
Study design: Case Report
Abstract: Objectives: This case report aims to evaluate the efficacy of zanubrutinib, a next-generation Bruton tyrosine kinase inhibitor (BTKi), in achieving durable disease control for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have experienced disease progression on ibrutinib, a first-generation BTKi. Methods: A patient with CLL/SLL who developed resistance to ibrutinib was treated with zanubrutinib. The patient's clinical response, including disease progression, symptom control, and adverse effects, was monitored over time. Results: The patient demonstrated significant and durable disease control following the initiation of zanubrutinib therapy. The treatment was well-tolerated, with no severe adverse effects reported, suggesting that zanubrutinib may be an effective therapeutic option for ibrutinib-resistant CLL/SLL patients. Discussion: The findings from this case report suggest that zanubrutinib may provide a viable treatment option for patients with CLL/SLL who have progressed on ibrutinib. Further studies and clinical trials are warranted to confirm these observations and to explore the broader applicability of zanubrutinib in managing ibrutinib-resistant CLL/SLL.
Source: Frontiers in Oncology
Authors: Zhenhui Lv, Ping Lu, Changhua Jing, Xuena Yi, Xueqiong Wu
Institution: Central Hospital of Zibo
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W4414487382